British Columbia-based, biodelivery technology
developer Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is
committed to the idea that better alternative methods for drug delivery exist
than inhalation. A recent article discussing the company reads, “Swallowed
medications have historically been slower to provide effective action than
inhaled ones, leading substance users looking for a quick fix to lean toward
the latter. But the deleterious and deadly consequences of smoking tobacco
products have been publicly acknowledged for decades, though hardly stemming
the tide of nicotine addiction as one generation succeeds another. . . . The
continued preference for the rapid delivery of inhaled drug substances has led
many researchers to seek alternatives beyond deterrence campaigns.
DehydraTECH’s newest formulation was recently shown to deliver 811% more CBD
into the bloodstream than generic industry control formulations, nearly
doubling the capacity of existing DehydraTECH technology. It was additionally
shown to deliver 1,937% more CBD across the blood-brain barrier into brain tissue
than generic industry-control formulations and 487% more than the original
DehydraTECH technology (http://ibn.fm/YEn9J).”
To view the full article, visit http://ibn.fm/T4TEF
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery
platforms. The company’s patented DehydraTECH drug-delivery technology changes
the way active pharmaceutical ingredients enter the bloodstream, promoting
healthier ingestion methods, lower overall dosing and higher effectiveness for
lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time
of onset and masks unwanted tastes for orally administered bioactive molecules
including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs
(“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to
multiple companies in the cannabis industry for use in cannabinoid beverages,
edibles and oral products, as well as to a world-leading tobacco producer for
the development of smokeless, oral-based nicotine products. Lexaria operates a
licensed, in-house research laboratory and holds a robust intellectual-property
portfolio with 16 patents granted and over 60 patents pending worldwide. For
more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment